AI Article Synopsis
- Multiple myeloma (MM) is a type of cancer that causes abnormal growth of plasma cells, leading to symptoms like anemia, kidney problems, and severe bone pain due to bone damage.
- Polymethylmethacrylate (PMMA) bone cement is commonly used for repairing bones after surgeries related to MM, known for its strong and quick-setting qualities.
- Research shows that PMMA loaded with 17-AAG can inhibit tumor growth and spread in live models, while also promoting cancer cell death by affecting specific proteins involved in apoptosis.
Article Abstract
Multiple myeloma (MM) is a monoclonal malignancy characterized by abnormal proliferation of plasma cells. The disease clinically manifests as anemia, hypercalcemia, renal insufficiencies, and osteolytic damage. Osteolytic damage goes with severe bone pain, spinal instability, and pathological fracture, symptoms that are collectively referred to as multiple myeloma bone disease (MMBD). Polymethylmethacrylate (PMMA) bone cement is widely used for bone repair after MMBD surgery, owing to its excellent biomechanical properties and fast curing. To date, however, efficacy of drug-loading PMMA in inhibition of tumor growth and angiogenesis remains unknown. Here, we report that 17-AAG-loaded PMMA bone cement inhibits MM growth in vivo and suppresses tumor diffusion to peripheral tissues. In addition, 17-AAG-loaded PMMA promotes MM apoptosis by downregulating Bax and active Caspase-3.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10238-021-00786-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!